2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Biological Therapies, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, CHIP, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

5509 Real-world outcomes and prognostic factors in pediatric chronic myeloid leukemia: A multicenter study from China

Wenbin An, Xingchen Wang2, Fenying Zhao3, Xue Li4, Lingzhen Wang, PhD5, Ningling Wang, MD6, Fu Li7, Futian Ma, MD, PhD8, Xiangling He9, Wenpeng Hao10, Xue Han11, Yan Gu12, Jianping Liu13, Xiaofan Zhu, MD14, Wenyu Yang15
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases,, Pediatric Hematology Oncology, Hangzhou, China
4 Qilu Hospital of Shandong University, Pediatrics, Jinan, China
5 the affiliated hospital of Qingdao University, Qingdao, China
6 The Second Affiliated Hospital of Anhui Medical University,Pediatric Hematology and Oncology, Hefei, China
7 Children's Hospital Affiliated to Shandong University, Hematology and Oncology, Jinan, China
8 Department of Hematology, Hebei Children's Hospital, Hematology, Shijiazhuang, China
9 Children's Medical Center, Hunan Provincial People's Hospital/First Hospital of Hunan Normal University, Hematology and Oncology, Changsha, China
10 Hematology and Tumor Research Center of Harbin First Hospital, Harbin, China
11 Department of Hematology, Kaifeng Children's Hospital, kaifeng, China
12 Pediatric Hematology Department, The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital), Jinan, China
13 Department of Pediatrics, Inner Mongolia Autonomous Region Maternal and Child Health Hospital, Hohhot, China
14 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
15 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Background:? Chronic myeloid leukemia (CML) is rare in children, with distinct clinical features from adults. While the EUTOS long-term survival (ELTS) score and 3-month early molecular response (EMR) are established prognostic markers in adults, their utility in pediatric patients requires validation in real-world settings. This study evaluated clinical characteristics, treatment patterns, and prognostic factors in a large Chinese pediatric CML cohort.

Methods:? This retrospective, multicenter study enrolled 248 chronic-phase CML patients (<18 years) from 13 centers of the China Children CML Cooperative Group (July 2007–September 2025). Most (89.9%) received first-line imatinib. Endpoints included progression-free survival (PFS), failure-free survival (FFS), event-free survival (EFS), and cumulative incidence of major molecular response (MMR) and deep molecular response (DMR). Survival analyses used Kaplan-Meier methods and multivariable Cox regression.

Results:?The median age at diagnosis was 9.3 years (range 0.5–17.8), with a male predominance. Most patients (97%) harbored the p210 BCR::ABL1 transcript. With a median follow-up of 45.3 months, 5-year OS reached 98.9% (95% CI: 97.3–100.0) and 5-year PFS 96.2% (95% CI: 93.5–98.9). EMR at 3 months emerged as a powerful predictor of long-term outcomes: patients with BCR::ABL1 ≤10% IS achieved MMR significantly faster (median 9 vs. 24 months, p<0.001) and DMR faster (median 18 vs. 50 months, p<0.001) than those with >10% IS. Similarly, a transcript log-reduction ≥0.65 at 3 months correlated with superior 12-month MMR rates (71.4% vs. 20%, HR 2.43, p=0.003) and 24-month DMR rates (63.6% vs. 33.1%, HR 2.82, p=0.011). EMR also predicted better long-term clinical durability, with 5-year EFS of 74.5% in the ≤10% group vs. 49.7% in the >10% group (HR 2.89, p=0.0006) and 5-year FFS of 73.6% vs. 47.8% (HR 2.92, p=0.004). In stark contrast, the baseline ELTS score lacked prognostic utility for survival endpoints: 5-year PFS was nearly identical among low, intermediate, and high groups (97.6% ,97.1%, and 100%, p=0.88), with only non-significant trends favoring low-risk status for EFS (73.7%, 67.9%, and 46.9%, p=0.1) and FFS (72.7%, 67.9%, and 46.9%, p=0.14)). These findings persisted even after excluding patients who switched TKIs, suggesting that proactive management of suboptimal responses mitigates baseline risk stratification in pediatric practice. Regarding TKI selection, 89.9% of patients initiated imatinib as first-line therapy, while 10.1% received frontline 2G-TKIs (dasatinib 60%, nilotinib 20%, flumatinib 20%). Among patients remaining on initial therapy, frontline 2G-TKIs and imatinib yielded comparable median time to MMR (12 months for both; 12-month MMR rate 58.7% vs. 54.0%, p=0.212). However, 2G-TKIs drove significantly deeper and faster molecular responses: the 24-month DMR rate was 100% with 2G-TKIs vs. 52.5% with imatinib (p=0.008), with a median time to DMR of 15 months vs. 24 months. While a higher proportion of 2G-TKI-treated patients met consensus criteria for treatment-free remission (TFR) eligibility (38.9% vs. 22.6%), this difference did not reach statistical significance (p=0.38, OR 1.71, 95% CI 0.60–4.86). Safety analyses revealed grade 3/4 adverse events in 14% of patients, most commonly myalgia/arthralgia with imatinib and serous effusions with dasatinib. Growth retardation was observed across the cohort, with a mean decline in height standard deviation score (SDS) of -0.82 from diagnosis to last follow-up (p=0.002), though no significant difference in height outcomes was detected between imatinib and 2G-TKI recipients in multivariable analysis.

Conclusion:? TKI therapy achieves excellent survival in Chinese pediatric CML. The 3-month EMR is a robust predictor of long-term outcomes, whereas the ELTS score lacks prognostic utility in this cohort. Frontline 2G-TKIs accelerate DMR attainment, supporting their potential role in facilitating future TFR strategies. Early molecular monitoring should supersede adult-derived risk scores in pediatric CML management.

Wenbin An: No relevant conflicts of interest to declare.